Base de dados : MEDLINE
Pesquisa : D02.092.877.883.099 [Categoria DeCS]
Referências encontradas : 7775 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 778 ir para página                         

  1 / 7775 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241711
[Au] Autor:Wang ZY; Liu YY; Liu GH; Lu HB; Mao CY
[Ad] Endereço:Department of Cardiology, China-Japan Union Hospital, Jilin University, Changchun, PR China.
[Ti] Título:l-Carnitine and heart disease.
[So] Source:Life Sci;194:88-97, 2018 Feb 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cardiovascular disease (CVD) is a key cause of deaths worldwide, comprising 15-17% of healthcare expenditure in developed countries. Current records estimate an annual global average of 30 million cardiac dysfunction cases, with a predicted escalation by two-three folds for the next 20-30years. Although ß-blockers and angiotensin-converting-enzymes are commonly prescribed to control CVD risk, hepatotoxicity and hematological changes are frequent adverse events associated with these drugs. Search for alternatives identified endogenous cofactor l-carnitine, which is capable of promoting mitochondrial ß-oxidation towards a balanced cardiac energy metabolism. l-Carnitine facilitates transport of long-chain fatty acids into the mitochondrial matrix, triggering cardioprotective effects through reduced oxidative stress, inflammation and necrosis of cardiac myocytes. Additionally, l-carnitine regulates calcium influx, endothelial integrity, intracellular enzyme release and membrane phospholipid content for sustained cellular homeostasis. Carnitine depletion, characterized by reduced expression of "organic cation transporter-2" gene, is a metabolic and autosomal recessive disorder that also frequently associates with CVD. Hence, exogenous carnitine administration through dietary and intravenous routes serves as a suitable protective strategy against ventricular dysfunction, ischemia-reperfusion injury, cardiac arrhythmia and toxic myocardial injury that prominently mark CVD. Additionally, carnitine reduces hypertension, hyperlipidemia, diabetic ketoacidosis, hyperglycemia, insulin-dependent diabetes mellitus, insulin resistance, obesity, etc. that enhance cardiovascular pathology. These favorable effects of l-carnitine have been evident in infants, juvenile, young, adult and aged patients of sudden and chronic heart failure as well. This review describes the mechanism of action, metabolism and pharmacokinetics of l-carnitine. It specifically emphasizes upon the beneficial role of l-carnitine in cardiomyopathy.
[Mh] Termos MeSH primário: Cardiotônicos/uso terapêutico
Carnitina/uso terapêutico
Cardiopatias/tratamento farmacológico
Coração/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Arritmias Cardíacas/tratamento farmacológico
Arritmias Cardíacas/metabolismo
Arritmias Cardíacas/patologia
Cardiotônicos/metabolismo
Carnitina/metabolismo
Cardiopatias/metabolismo
Cardiopatias/patologia
Seres Humanos
Traumatismo por Reperfusão Miocárdica/tratamento farmacológico
Traumatismo por Reperfusão Miocárdica/metabolismo
Traumatismo por Reperfusão Miocárdica/patologia
Miocárdio/metabolismo
Miocárdio/patologia
Disfunção Ventricular/tratamento farmacológico
Disfunção Ventricular/metabolismo
Disfunção Ventricular/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cardiotonic Agents); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  2 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337668
[Au] Autor:Badawi AA; Hegazy MM; Louis D; Eldegwy MA
[Ad] Endereço:1Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy, Cairo University Cairo, Egypt.
[Ti] Título:Solving manufacturing problems for L-carnitine-L-tartrate to improve the likelihood of successful product scale-up.
[So] Source:Acta Pharm;67(4):511-525, 2017 Dec 20.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:L-carnitine-L-tartrate, a non-essential amino acid, is hygroscopic. This causes a problem in tablet production due to pronounced adhesion of tablets to punches. A 33 full factorial design was adopted to suggest a tablet formulation. Three adsorbents were suggested (Aerosil 200, Aerosil R972, talc) to reduce stickiness at three concentrations (1, 3 and 5 %), and three fillers (mannitol, Avicel PH 101, Dibasic calcium phosphate) were chosen to prepare 27 formulations. Micromeritic properties of formulations were studied, and tablets were prepared by wet granulation. Absence of picking, sticking or capping, recording of sufficient hardness, acceptable friability and tablet ejection force indicated formulation success. The resulting formulation prepared using Avicel PH 101 and 1 % Aerosil 200 was submitted to further investigation in order to choose the most suitable compression conditions using a 33 full factorial design. Variables included compression force, tableting rate and magnesium stearate (lubricant) concentration. The formulation prepared at compression force of 25 kN, using 2 % magnesium stearate, at a production rate of 30 tablets/ minute, was found to be the most appropriate scale up candidate.
[Mh] Termos MeSH primário: Carnitina/síntese química
Comprimidos/síntese química
Tartaratos/síntese química
[Mh] Termos MeSH secundário: Química Farmacêutica/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tablets); 0 (Tartrates); S7UI8SM58A (Carnitine); W4888I119H (tartaric acid)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  3 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29213153
[Au] Autor:Céspedes N; Valencia A; Echeverry CA; Arce-Plata MI; Colón C; Castiñeiras DE; Hurtado PM; Cocho JA; Herrera S; Arévalo-Herrera M
[Ad] Endereço:Malaria Vaccine and Drug Development Center (MVDC), Cali, Colombia.
[Ti] Título:Reference values of amino acids, acylcarnitines and succinylacetone by tandem mass spectrometry for use in newborn screening in southwest Colombia.
[So] Source:Colomb Med (Cali);48(3):113-119, 2017 Sep 30.
[Is] ISSN:1657-9534
[Cp] País de publicação:Colombia
[La] Idioma:eng
[Ab] Resumo:Introduction: Inborn errors of metabolism (IEM) represent an important public health problem due to current diagnosis and treatment limitations, poor life quality of affected patients, and consequent untimely child death. In contrast to classical methods, tandem mass spectrometry (MS/MS) has allowed simultaneous evaluation of multiple metabolites associated with IEM offering higher sensitivity, low false positive rates and high throughput. Aims: Determine concentration levels for amino acids and acylcarnitines in blood of newborns from Colombia, to establish reference values for further use in diagnosis of IEM. Methods: Implementation of a method to determine amino acids, acylcarnitines and succinylacetone in newborn dried blood spots using MS/MS, and its application in a cross-sectional study conducted in 891 healthy neonates from Cali and Quibdo cities is described. Results: fifty-seven analytes that allow the diagnosis of more than 40 different pathologies were tested. The method showed to be linear, precise and accurate. Healthy neonates 1-18 days of age were included, 523 from Cali and 368 from Quibdo; 52% male and 48% female. Age-related differences on the concentration levels of amino acids and acylcarnitines were observed whereas no significant differences by gender were found. Conclusion: The study has contributed to reveal the usual concentration levels of amino acids, acylcarnitines and succinylacetone that could be used as reference for the establishment of a newborn metabolic screening program in Colombia.
[Mh] Termos MeSH primário: Aminoácidos/sangue
Carnitina/análogos & derivados
Heptanoatos/sangue
Erros Inatos do Metabolismo/diagnóstico
Espectrometria de Massas em Tandem/métodos
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Carnitina/sangue
Colômbia
Estudos Transversais
Reações Falso-Positivas
Seres Humanos
Recém-Nascido
Erros Inatos do Metabolismo/sangue
Valores de Referência
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Biomarkers); 0 (Heptanoates); 0 (acylcarnitine); 51568-18-4 (succinylacetone); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180109
[Lr] Data última revisão:
180109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.25100/cm.v48i3.2180


  4 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252954
[Au] Autor:Vollmer JP; Haen S; Wolburg H; Lehmann R; Steiner J; Reddersen S; Fend F; Fallier-Becker P
[Ad] Endereço:Institute of Anaesthesiology, Klinikum Stuttgart, Germany.
[Ti] Título:Propofol Related Infusion Syndrome: Ultrastructural Evidence for a Mitochondrial Disorder.
[So] Source:Crit Care Med;46(1):e91-e94, 2018 Jan.
[Is] ISSN:1530-0293
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of this report of a fatal propofol-related infusion syndrome in a young adult was to present-to our knowledge for the first time-direct ultrastructural evidence for the central role of mitochondrial damage in the pathogenesis of this syndrome. DATA SOURCES: Histological and electron microscopical analysis of liver, skeletal, and heart muscle obtained by autopsy and blood obtained from patient. STUDY SELECTION: Case report. DATA EXTRACTION: In addition to conventional macroscopical and histological investigations, electron-microscopical analysis of myocardial- and skeletal muscle and liver tissue obtained at autopsy from a young man was performed in order to search for ultrastructural changes of mitochondria. Acylcarnitine concentrations of his blood were determined by ultra-high performance liquid chromatography mass spectrometry. DATA SYNTHESIS: A 19-year-old male was admitted with acute left-side hemiparesis. The patient was intubated, then propofol infusion started, and a craniotomy was performed to remove an intracerebral hematoma. In the postoperative period, the patient presented with elevated intracranial pressure and brain edema. After repeat surgery, the patient showed impaired systolic left ventricular function, increasing fever, anuria, hyperkalemia, and metabolic acidosis, and he finally expired. Electron microscopy revealed dark, electron dense amorphous structures associated with mitochondria in heart muscle and liver tissue obtained at autopsy. Peripheral blood analysis revealed increased levels of acetyl-, propionyl-, butyryl-, malonyl-, and valeryl-carnitine as an indicator for propofol-related infusion syndrome, as well as for propofol-mediated inhibition of free fatty acid uptake into mitochondria, affecting beta-oxidation. CONCLUSIONS: Electron dense bodies found in association with mitochondria in muscle and liver cells probably correspond to accumulation of free fatty acid provide direct morphological evidence for the mitochondrial damage in propofol-related infusion syndrome.
[Mh] Termos MeSH primário: Doenças Mitocondriais/induzido quimicamente
Doenças Mitocondriais/patologia
Síndrome da Infusão de Propofol/patologia
[Mh] Termos MeSH secundário: Carnitina/análogos & derivados
Carnitina/sangue
Craniotomia
Hematoma Subdural Intracraniano/cirurgia
Seres Humanos
Infusões Intravenosas
Masculino
Microscopia Eletrônica
Mitocôndrias Cardíacas/efeitos dos fármacos
Mitocôndrias Cardíacas/patologia
Mitocôndrias Hepáticas/efeitos dos fármacos
Mitocôndrias Hepáticas/patologia
Mitocôndrias Musculares/efeitos dos fármacos
Mitocôndrias Musculares/patologia
Complicações Pós-Operatórias/induzido quimicamente
Complicações Pós-Operatórias/patologia
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (acylcarnitine); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1097/CCM.0000000000002802


  5 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28745680
[Au] Autor:Belousova ED
[Ad] Endereço:Department of Psychoneurology and Epileptology ,Research and Clincal Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, Russia.
[Ti] Título:[The decreased level of plasma carnitine in patients with epilepsy].
[Ti] Título:Snizhenie kontsentratsii karnitina u patsientov s épilepsiei..
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;117(6):106-110, 2017.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Antiepileptic drugs (AEDs) have long been known to affect carnitine metabolism, dropping the plasma free carnitine. Valproate (VPA) was considered to be the strongest carnitine-reducing agent. VPA-induced hyperammonemic encephalopathy and hepatotoxicity are well known, and pre-existing carnitine deficiency can be a predisposing factor, especially in congenital metabolic disorders. Several studies have shown that carnitine supplementation in patients receiving VPA to result in subjective and objective improvements and to prevent VPA-induced hepatotoxicity and encephalopathy, in parallel with increases in carnitine serum concentrations. Level of free plasma carnitine <20 micromol/l (syn. carnitine deficiency) in patients with epilepsy (in 15-30% of cases) may occur not only with administration of VPA but with administration of other AEDs (phenobarbital, phenytoin, carbamazepine) and low nutritional intake of carnitine. Some findings indicate that the number of AEDs used is a risk factor for carnitine deficiency. It was established that body weight, height and multidrug therapy are significantly associated with low level of free plasma in epileptic patients. Carnitine deficiency can have severe consequences; but most epileptic patients suffering from it are asymptomatic. Although carnitine deficiency is not uncommon among patients receiving AEDs, it seems not necessary to routinely monitor carnitine levels in epileptic ambulatory patients, this is reasonable only in groups of risk. L-carnitine supplementation is clearly indicated in case of VPA-induced hepatotoxicity (i.v. administration) VPA overdose (i.v. administration), primary carnitine-transporter defect and is strongly recommended in specific secondary carnitine deficiency syndromes, symptomatic VPA-associated hyperammonemia, infants and young children receiving VPA, especially those younger than 2 years, patients with a complex neurologic disorder, who are receiving multiple AEDs, patients who have risk factors for hepatotoxicity and carnitine insufficiency. In the absence of double blind trials, clinical practice is based on empiric observation, clinical experience, and theory. Well-designed studies of specific and general uses of L-carnitine replacement therapy in patients with epilepsy are needed.
[Mh] Termos MeSH primário: Anticonvulsivantes/efeitos adversos
Cardiomiopatias/induzido quimicamente
Carnitina/sangue
Carnitina/deficiência
Epilepsia/sangue
Epilepsia/tratamento farmacológico
Hiperamonemia/induzido quimicamente
Doenças Musculares/induzido quimicamente
[Mh] Termos MeSH secundário: Anticonvulsivantes/uso terapêutico
Peso Corporal
Carbamazepina/efeitos adversos
Carbamazepina/uso terapêutico
Cardiomiopatias/tratamento farmacológico
Carnitina/uso terapêutico
Criança
Feminino
Seres Humanos
Hiperamonemia/tratamento farmacológico
Lactente
Masculino
Doenças Musculares/tratamento farmacológico
Síndromes Neurotóxicas/tratamento farmacológico
Síndromes Neurotóxicas/etiologia
Fatores de Risco
Ácido Valproico/efeitos adversos
Ácido Valproico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticonvulsants); 33CM23913M (Carbamazepine); 614OI1Z5WI (Valproic Acid); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro201711761106-110


  6 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953637
[Au] Autor:Cattaneo CI; Ressico F; Valsesia R; D'Innella P; Ballabio M; Fornaro M
[Ad] Endereço:aAsl Novara, Department of Mental Health - Outpatient Unit bAsl Novara, Department of Mental Health - Inpatient Unit- Borgomanero, Novara cDepartment of Neuroscience, University School of Naples "Federico II", Naples, Italy.
[Ti] Título:Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
[So] Source:Medicine (Baltimore);96(39):e8117, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Valproic Acid is a commonly used psychiatric drug primarily used as a mood stabilizer. Mild hyperammonemia is a Valproic Acid common adverse effect. This report presents an example of treated hyperammonemia on Valproic acid therapy managed with L-carnitine administration in BD patients characterized by sudden vulnerability. PATIENT CONCERNS: We report the case of a 29-year-old man suffering from bipolar disorder (BD) and substance use disorder who exhibited sudden altered mental status upon admittance to the inpatient unit. The patient was started on Valproic acid with no improvement. DIAGNOSES: The patient had remarkably high ammonia levels (594 µg/dL) without hepatic insufficiency, likely due to his valproate treatment. INTERVENTIONS: The patient was administered lactulose, intravenous hydration, and i.v. levocarnitine supplementation 4.5 g/day. OUTCOMES: The administration leads to reduction of ammonia levels to 99 µg/dL within 12 hours upon initiation of carnitine therapy and progressive restore of his mental status within 24 hours. LESSONS: Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine. An interesting aspect of this case was how rapidly the patient responded to the carnitine therapy.
[Mh] Termos MeSH primário: Antimaníacos/efeitos adversos
Transtorno Bipolar/tratamento farmacológico
Carnitina/administração & dosagem
Hiperamonemia/tratamento farmacológico
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
Ácido Valproico/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Hiperamonemia/induzido quimicamente
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antimanic Agents); 614OI1Z5WI (Valproic Acid); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008117


  7 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28942964
[Au] Autor:Kim HI; Raffler J; Lu W; Lee JJ; Abbey D; Saleheen D; Rabinowitz JD; Bennett MJ; Hand NJ; Brown C; Rader DJ
[Ad] Endereço:Department of Genetics, The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA 19104, USA.
[Ti] Título:Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport.
[So] Source:Am J Hum Genet;101(4):489-502, 2017 Oct 05.
[Is] ISSN:1537-6605
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Genome-wide association studies have identified a signal at the SLC22A1 locus for serum acylcarnitines, intermediate metabolites of mitochondrial oxidation whose plasma levels associate with metabolic diseases. Here, we refined the association signal, performed conditional analyses, and examined the linkage structure to find coding variants of SLC22A1 that mediate independent association signals at the locus. We also employed allele-specific expression analysis to find potential regulatory variants of SLC22A1 and demonstrated the effect of one variant on the splicing of SLC22A1. SLC22A1 encodes a hepatic plasma membrane transporter whose role in acylcarnitine physiology has not been described. By targeted metabolomics and isotope tracing experiments in loss- and gain-of-function cell and mouse models of Slc22a1, we uncovered a role of SLC22A1 in the efflux of acylcarnitines from the liver to the circulation. We further validated the impacts of human variants on SLC22A1-mediated acylcarnitine efflux in vitro, explaining their association with serum acylcarnitine levels. Our findings provide the detailed molecular mechanisms of the GWAS association for serum acylcarnitines at the SLC22A1 locus by functionally validating the impact of SLC22A1 and its variants on acylcarnitine transport.
[Mh] Termos MeSH primário: Carnitina/análogos & derivados
Regulação da Expressão Gênica
Fígado/metabolismo
Doenças Metabólicas/genética
Transportador 1 de Cátions Orgânicos/genética
Polimorfismo de Nucleotídeo Único
[Mh] Termos MeSH secundário: Alelos
Processamento Alternativo
Animais
Transporte Biológico
Sistemas CRISPR-Cas
Carnitina/sangue
Carnitina/farmacocinética
Células Cultivadas
Estudos de Coortes
Feminino
Estudo de Associação Genômica Ampla
Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Masculino
Doenças Metabólicas/sangue
Doenças Metabólicas/metabolismo
Metabolômica
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
Camundongos Knockout
Transportador 1 de Cátions Orgânicos/antagonistas & inibidores
Transportador 1 de Cátions Orgânicos/metabolismo
Distribuição Tecidual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Organic Cation Transporter 1); 0 (acylcarnitine); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE


  8 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28866099
[Au] Autor:Takano M; Kamei H; Nagahiro M; Kawami M; Yumoto R
[Ad] Endereço:Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan. Electronic address: takanom@hiroshima-u.ac.jp.
[Ti] Título:Nicotine transport in lung and non-lung epithelial cells.
[So] Source:Life Sci;188:76-82, 2017 Nov 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Nicotine is rapidly absorbed from the lung alveoli into systemic circulation during cigarette smoking. However, mechanism underlying nicotine transport in alveolar epithelial cells is not well understood to date. In the present study, we characterized nicotine uptake in lung epithelial cell lines A549 and NCI-H441 and in non-lung epithelial cell lines HepG2 and MCF-7. MATERIALS AND METHODS: Characteristics of [ H]nicotine uptake was studied using these cell lines. KEY FINDINGS: Nicotine uptake in A549 cells occurred in a time- and temperature-dependent manner and showed saturation kinetics, with a Km value of 0.31mM. Treatment with some organic cations such as diphenhydramine and pyrilamine inhibited nicotine uptake, whereas treatment with organic cations such as carnitine and tetraethylammonium did not affect nicotine uptake. Extracellular pH markedly affected nicotine uptake, with high nicotine uptake being observed at high pH up to 11.0. Modulation of intracellular pH with ammonium chloride also affected nicotine uptake. Treatment with valinomycin, a potassium ionophore, did not significantly affect nicotine uptake, indicating that nicotine uptake is an electroneutral process. For comparison, we assessed the characteristics of nicotine uptake in another lung epithelial cell line NCI-H441 and in non-lung epithelial cell lines HepG2 and MCF-7. Interestingly, these cell lines showed similar characteristics of nicotine uptake with respect to pH dependency and inhibition by various organic cations. SIGNIFICANCE: The present findings suggest that a similar or the same pH-dependent transport system is involved in nicotine uptake in these cell lines. A novel molecular mechanism of nicotine transport is proposed.
[Mh] Termos MeSH primário: Transporte Biológico/efeitos dos fármacos
Células Epiteliais/metabolismo
Pulmão/metabolismo
Nicotina/farmacocinética
[Mh] Termos MeSH secundário: Carnitina/farmacologia
Células Cultivadas
Difenidramina/farmacologia
Interações Medicamentosas
Seres Humanos
Concentração de Íons de Hidrogênio
Pirilamina/farmacologia
Temperatura Ambiente
Tetraetilamônio/farmacologia
Fatores de Tempo
Trítio/metabolismo
Valinomicina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
10028-17-8 (Tritium); 2001-95-8 (Valinomycin); 66-40-0 (Tetraethylammonium); 6M3C89ZY6R (Nicotine); 8GTS82S83M (Diphenhydramine); HPE317O9TL (Pyrilamine); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170904
[St] Status:MEDLINE


  9 / 7775 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28846683
[Au] Autor:Boemer F; Detilleux J; Cello C; Amory H; Marcillaud-Pitel C; Richard E; van Galen G; van Loon G; Lefère L; Votion DM
[Ad] Endereço:Biochemical Genetics Laboratory, CHU Sart Tilman, University of Liege, Liege, Belgium.
[Ti] Título:Acylcarnitines profile best predicts survival in horses with atypical myopathy.
[So] Source:PLoS One;12(8):e0182761, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Equine atypical myopathy (AM) is caused by hypoglycin A intoxication and is characterized by a high fatality rate. Predictive estimation of survival in AM horses is necessary to prevent unnecessary suffering of animals that are unlikely to survive and to focus supportive therapy on horses with a possible favourable prognosis of survival. We hypothesized that outcome may be predicted early in the course of disease based on the assumption that the acylcarnitine profile reflects the derangement of muscle energetics. We developed a statistical model to prognosticate the risk of death of diseased animals and found that estimation of outcome may be drawn from three acylcarnitines (C2, C10:2 and C18 -carnitines) with a high sensitivity and specificity. The calculation of the prognosis of survival makes it possible to distinguish the horses that will survive from those that will die despite severe signs of acute rhabdomyolysis in both groups.
[Mh] Termos MeSH primário: Carnitina/análogos & derivados
Doenças dos Cavalos/sangue
Doenças Musculares/veterinária
[Mh] Termos MeSH secundário: Animais
Carnitina/sangue
Doenças dos Cavalos/mortalidade
Cavalos
Doenças Musculares/sangue
Doenças Musculares/mortalidade
Prognóstico
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (acylcarnitine); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182761


  10 / 7775 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28791854
[Au] Autor:Xu Y; Jiang W; Chen G; Zhu W; Ding W; Ge Z; Tan Y; Ma T; Cui G
[Ad] Endereço:Department of Gastroenterology, the Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, China.
[Ti] Título:L-carnitine treatment of insulin resistance: A systematic review and meta-analysis.
[So] Source:Adv Clin Exp Med;26(2):333-338, 2017 Mar-Apr.
[Is] ISSN:1899-5276
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: L-carnitine has been used for several years as an adjuvant therapy in oxidative stress, blood sugar, high-sensitivity C-reactive protein (CRP), anemia, etc. However, the efficacy of L-carnitine treating insulin resistance (IR) remains controversial. Homeostasis model assessment of Insulin Resistance (HOMA-IR) is widely used in the clinical evaluation of patients with IR. OBJECTIVES: A meta-analysis, including randomized controlled trials (RCTs), was performed to assess the effect of L-carnitine on HOMA-IR patients. MATERIAL AND METHODS: The Cochrane Library, PubMed, and EMBASE databases were systematically searched to identify RCTs which evaluated the effects of L-carnitine on HOMA-IR patients. We screened relevant studies according to predefined inclusion and exclusion criteria. In the selected articles, we extracted the data: study design, sample size, age, L-carnitine dose and regimen, body mass index (BMI) of patients, mode of administration, study duration and study outcomes. RESULTS: A total of 5 studies were included for the meta-analysis. The result showed L-carnitine was useful in the treatment of IR (WMD -0.724, CI -0.959 -0.488, p < 0.0001). Evaluation at 3, 6, 9, 12 months, the p-values were 0.875, 0.165, 0.031, 0, 007, respectively. CONCLUSIONS: L-carnitine was useful in treating patients with IR. L-carnitine can treat IR more effectively with prolonging the medication time. However, more RCTs with long-term L-carnitine treatment of IR are needed to confirm the viewpoint.
[Mh] Termos MeSH primário: Glicemia/metabolismo
Carnitina/uso terapêutico
Homeostase/efeitos dos fármacos
Resistência à Insulina
[Mh] Termos MeSH secundário: Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Blood Glucose); S7UI8SM58A (Carnitine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170908
[Lr] Data última revisão:
170908
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170810
[St] Status:MEDLINE
[do] DOI:10.17219/acem/61609



página 1 de 778 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde